A screen of Crohn’s disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells

Mucosal Immunology

Volumn 12, Issue 2, 2019, Pages 457-467

  Chang, Yu Ling ^a   Rossetti, Maura ^a   Vlamakis, Hera ^b   Casero, David ^a   Sunga, Gemalene ^a   Harre, Nicholas ^a   Miller, Shelley ^a   Humphries, Romney ^a   Stappenbeck, Thaddeus ^c   Simpson, Kenneth W ^d   Sartor, R Balfour ^e   Wu, Gary ^f   Lewis, James ^g   Bushman, Frederic ^g   McGovern, Dermot P B ^h   Salzman, Nita ⁱ   Borneman, James ^j   Xavier, Ramnik ^b   Huttenhower, Curtis ^b   Braun, Jonathan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Cornell University ^*  (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; GAMMA INTERFERON; GLUCOSE TRANSPORTER 1; INTERLEUKIN 17; INTERLEUKIN 4;

APOPTOSIS; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFECTOR CELL; ENERGY METABOLISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; METABOLIC INHIBITION; METABOLITE; MICROBIAL METABOLITE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH17 CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL RESPIRATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MASS SCREENING; METABOLISM; MICROBIOLOGY; MICROFLORA;

APOPTOSIS; ASCORBIC ACID; CELL DIFFERENTIATION; CELL RESPIRATION; CELLS, CULTURED; CROHN DISEASE; ENERGY METABOLISM; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MASS SCREENING; MICROBIOTA; TH17 CELLS;

EID: 85046035681     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/s41385-018-0022-7     Document Type: Article

References (70)

1. Integrative HMPRNC. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16, 276–289 (2014).
2. Huttenhower, C., Kostic, A. D. & Xavier, R. J. Inflammatory bowel disease as a model for translating the microbiome. Immunity 40, 843–854 (2014).
3. Sartor, R. B. & Wu, G. D. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 152, 327–339.e324 (2017).
4. Brestoff, J. R. & Artis, D. Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14, 676–684 (2013).
5. Dorrestein, P. C., Mazmanian, S. K. & Knight, R. Finding the missing links among metabolites, microbes, and the host. Immunity 40, 824–832 (2014).
6. Thorburn, A. N., Macia, L. & Mackay, C. R. Diet, metabolites, and “western-lifestyle” inflammatory diseases. Immunity 40, 833–842 (2014).
7. Kaiko, G. E. et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell 167, 1137 (2016).
8. Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).
9. Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15, 382–392 (2014).
10. Tong, M. et al. Reprograming of gut microbiome energy metabolism by the FUT2 Crohn’s disease risk polymorphism. ISME J. 8, 2193–2206 (2014).
11. Lewis, J. D. et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe 18, 489–500 (2015).
12. Gao, Z. et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517 (2009).
13. Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013).
14. Chang, P. V., Hao, L., Offermanns, S. & Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl Acad. Sci. USA 111, 2247–2252 (2014).
15. Mascanfroni, I. D. et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha. Nat. Med. 21, 638–646 (2015).
16. Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the immune system. Science 336, 1268–1273 (2012).
17. Knights, D. et al. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med. 6, 107 (2014).
18. Khor, B., Gardet, A. & Xavier, R. J. Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307–317 (2011).
19. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
20. Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310–1316 (2006).
21. Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65–70 (2003).
22. Kleinschek, M. A. et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206, 525–534 (2009).
23. Bogaert, S. et al. Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol. 11, 61 (2010).
24. Kobayashi, T. et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut 57, 1682–1689 (2008).
25. Neurath, M. F. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 7, 6–19 (2014).
26. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).
27. Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N. Engl. J. Med. 367, 1519–1528 (2012).
28. Sands, B. E. et al. OP025: a randomized, double-blind placebo-controlled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy. J. Crohn’s Colitis 9, S15–S16 (2015).
29. Targan, S. R. et al. Mo2083: a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s disease. Gastroenterology 143, e26 (2012).
30. Colombel, J. F., Sendid, B., Jouault, T. & Poulain, D. Secukinumab failure in Crohn’s disease: the yeast connection? Gut 62, 800–801 (2013).
31. Maxwell, J. R. et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity 43, 739–750 (2015).
32. Morgan, X. C. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13, R79 (2012).
33. Wilson, N. J. et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8, 950–957 (2007).
34. Wang, C. et al. CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity. Cell 163, 1413–1427 (2015).
35. Pacheco, R. et al. Glutamate released by dendritic cells as a novel modulator of T cell activation. J. Immunol. 177, 6695–6704 (2006).
36. Wishart, D. S. et al. HMDB 3.0--The Human Metabolome Database in 2013. Nucleic Acids Res. 41, D801–D807 (2013).
37. Yun, J. et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350, 1391–1396 (2015).
38. Macintyre, A. N. et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20, 61–72 (2014).
39. Buck, M. D., O’Sullivan, D. & Pearce, E. L. T cell metabolism drives immunity. J. Exp. Med. 212, 1345–1360 (2015).
40. Slack, M., Wang, T. & Wang, R. T cell metabolic reprogramming and plasticity. Mol. Immunol. 68, 507–512 (2015).
41. Hancock, R. D. & Viola, R. Biotechnological approaches for L-ascorbic acid production. Trends Biotechnol. 20, 299–305 (2002).
42. DuPage, M. & Bluestone, J. A. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat. Rev. Immunol. 16, 149–163 (2016).
43. Sallusto, F. Heterogeneity of human CD4(+) T cells against microbes. Annu. Rev. Immunol. 34, 317–334 (2016).
44. Hong, J. M., Kim, J. H., Kang, J. S., Lee, W. J. & Hwang, Y. I. Vitamin C is taken up by human T cells via sodium-dependent vitamin C transporter 2 (SVCT2) and exerts inhibitory effects on the activation of these cells in vitro. Anat. Cell Biol. 49, 88–98 (2016).
45. Maratou, E. et al. Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur. J. Clin. Invest. 37, 282–290 (2007).
46. Rumsey, S. C. et al. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J. Biol. Chem. 272, 18982–18989 (1997).
47. Vera, J. C., Rivas, C. I., Fischbarg, J. & Golde, D. W. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 364, 79–82 (1993).
48. May, J. M., Mendiratta, S., Hill, K. E. & Burk, R. F. Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J. Biol. Chem. 272, 22607–22610 (1997).
49. Winkler, B. S., Orselli, S. M. & Rex, T. S. The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective. Free Radic. Biol. Med. 17, 333–349 (1994).
50. Hwang, N. R. et al. Oxidative modifications of glyceraldehyde-3-phosphate dehydrogenase play a key role in its multiple cellular functions. Biochem. J. 423, 253–264 (2009).
51. Shenton, D. & Grant, C. M. Protein S-thiolation targets glycolysis and protein synthesis in response to oxidative stress in the yeast Saccharomyces cerevisiae. Biochem. J. 374, 513–519 (2003).
52. Ravichandran, V., Seres, T., Moriguchi, T., Thomas, J. A. & Johnston, R. B. Jr. S-thiolation of glyceraldehyde-3-phosphate dehydrogenase induced by the phagocytosis-associated respiratory burst in blood monocytes. J. Biol. Chem. 269, 25010–25015 (1994).
53. Ullah, M. F., Khan, H. Y., Zubair, H., Shamim, U. & Hadi, S. M. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother. Pharmacol. 67, 103–110 (2011).
54. Franchi, L. et al. Inhibiting oxidative phosphorylation in vivo restrains Th17 effector responses and ameliorates murine colitis. J. Immunol. 198, 2735–2746 (2017).
55. Fiorani, M. et al. The mitochondrial transporter of ascorbic acid functions with high affinity in the presence of low millimolar concentrations of sodium and in the absence of calcium and magnesium. Biochim. Biophys. Acta 1848, 1393–1401 (2015).
56. Tsukaguchi, H. et al. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature 399, 70–75 (1999).
57. Savini, I., Rossi, A., Pierro, C., Avigliano, L. & Catani, M. V. SVCT1 and SVCT2: key proteins for vitamin C uptake. Amino Acids 34, 347–355 (2008).
58. Li, X., Cobb, C. E. & May, J. M. Mitochondrial recycling of ascorbic acid from dehydroascorbic acid: dependence on the electron transport chain. Arch. Biochem. Biophys. 403, 103–110 (2002).
59. Sasidharan Nair, V., Song, M. H. & Oh, K. I. Vitamin C facilitates demethylation of the Foxp3 enhancer in a Tet-dependent manner. J. Immunol. 196, 2119–2131 (2016).
60. Yue, X. et al. Control of Foxp3 stability through modulation of TET activity. J. Exp. Med. 213, 377–397 (2016).
61. Nishikimi, M., Fukuyama, R., Minoshima, S., Shimizu, N. & Yagi, K. Cloning and chromosomal mapping of the human nonfunctional gene for L-gulono-gamma-lactone oxidase, the enzyme for L-ascorbic acid biosynthesis missing in man. J. Biol. Chem. 269, 13685–13688 (1994).
62. Naidu, K. A. Vitamin C in human health and disease is still a mystery? An overview. Nutr. J. 2, 7 (2003).
63. Costa, K. C., Glasser, N. R., Conway, S. J. & Newman, D. K. Pyocyanin degradation by a tautomerizing demethylase inhibits Pseudomonas aeruginosa biofilms. Science 355, 170–173 (2017).
64. Vera, J. C. et al. Resolution of the facilitated transport of dehydroascorbic acid from its intracellular accumulation as ascorbic acid. J. Biol. Chem. 270, 23706–23712 (1995).
65. Amir Shaghaghi, M., Bernstein, C. N., Serrano Leon, A., El-Gabalawy, H. & Eck, P. Polymorphisms in the sodium-dependent ascorbate transporter gene SLC23A1 are associated with susceptibility to Crohn disease. Am. J. Clin. Nutr. 99, 378–383 (2014).
66. Hengstermann, S. et al. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin. Nutr. 27, 571–578 (2008).
67. Langille, M. G. et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 31, 814–821 (2013).
68. Abubucker, S. et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput. Biol. 8, e1002358 (2012).
69. Sokol, P. A., Darling, P., Woods, D. E., Mahenthiralingam, E. & Kooi, C. Role of ornibactin biosynthesis in the virulence of Burkholderia cepacia: characterization of pvdA, the gene encoding L-ornithine N(5)-oxygenase. Infect. Immun. 67, 4443–4455 (1999).
70. Mc, F. J. The nephelometer:aN instrument for estimating the number of bacteria in suspensions used for calculating the opsonic index and for vaccines. J. Am. Med. Assoc. XLIX, 1176–1178 (1907).